The Board of Directors considered and took on record the Un-audited Standalone Financial Results for the quarter and half year ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Samrat Pharmachem Limited reported a loss of ₹58.73 lakhs in Q2 FY26 against a profit of ₹266.11 lakhs in Q2 FY25, marking a sharp swing to negative territory. For H1 FY26, the company posted a loss of ₹81.62 lakhs versus a profit of ₹472.66 lakhs in H1 FY25. Revenue from operations grew modestly by about 12.4% YoY to ₹7,887 lakhs in Q2 (₹15,452 lakhs in H1, up 2.3% YoY), but a steep rise in raw material costs (up ~15% YoY in Q2) wiped out margins. The auditor (Shah & Savla LLP) issued a clean limited review report with no qualifications or emphasis of matter.
Despite topline growth, a sharp rise in input costs has pushed the company into operating losses for two consecutive quarters, which is a negative signal for near-term profitability and may weigh on the stock. However, cash from operations remains healthy at ₹1,977 lakhs in H1 FY26 (vs negative ₹265 lakhs a year ago), and the balance sheet carries low leverage, offering some comfort.